Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.75 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.66 |
| ▸ | CA3 | P07451 | 2/20 | 0.64 |
| ▸ | CA5A | P35218 | 2/20 | 0.64 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.64 |
| ▸ | CA4 | P22748 | 1/20 | 0.64 |
| ▸ | CA6 | P23280 | 1/20 | 0.64 |
| ▸ | CA7 | P43166 | 1/20 | 0.64 |
| ▸ | CA9 | Q16790 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11440052 | 1.00 | MEN1 (0.79) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL11440795 | 1.00 | MEN1 (0.79) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL2608503 | 0.91 | ALDH1A1 (0.74) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL29982917 | 0.89 | MEN1 (1.00) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL27889238 | 0.87 | ALDH1A1 (1.00) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL864397 | 0.83 | ALDH1A1 (0.82) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL570465 | 0.83 | CA3 (0.91) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL571461 | 0.82 | ALDH1A1 (0.65) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL3215133 | 0.81 | MEN1 (0.83) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL3221326 | 0.81 | MEN1 (0.83) | MEN1KMT2AALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773730-B1 | DRUG DELIVERY FORMULATIONS | UNIV CALIFORNIA (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12171877-B2 | Materials and methods for delivering compositions to selected tissues | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-24 | — | — | US | disclosed |
| EP-2178499-B1 | MATERIALS AND METHODS FOR DELIVERING COMPOSITIONS TO SELECTED TISSUES | UNIV CALIFORNIA (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11241380-B2 | Porous photonic crystals for drug delivery to the eye | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-08 | — | — | US | disclosed |
| US-20220000768-A9 | POROUS PHOTONIC CRYSTALS FOR DRUG DELIVERY TO THE EYE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-01-06 | — | — | US | disclosed |
| US-20210054017-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS INC (US) | 2021-02-25 | — | — | US | disclosed |
| EP-3773730-A1 | DRUG DELIVERY FORMULATIONS | The Regents of The University of California (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210000744-A1 | DRUG DELIVERY FORMULATIONS | UNIV CALIFORNIA (US) | 2021-01-07 | — | — | US | disclosed |
| WO-2019191132-A1 | DRUG DELIVERY FORMULATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-03 | — | — | WO | disclosed |
| EP-3381446-A1 | POROUS PHOTONIC CRYSTALS FOR DRUG DELIVERY TO THE EYE | The Regents of The University of California (US) | 2018-10-03 | — | — | EP | disclosed |
| US-20130224302-A1 | POROUS PHOTONIC CRYSTALS FOR DRUG DELIVERY TO THE EYE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-29 | — | — | US | disclosed |
| CN-101815504-A | Be used for material and method to the selected tissues delivering compositions | UNIV CALIFORNIA | 2010-08-25 | — | — | CN | disclosed |
| US-20100196435-A1 | MATERIALS AND METHODS FOR DELIVERING COMPOSITIONS TO SELECTED TISSUES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-08-05 | — | — | US | disclosed |
| EP-2178499-A2 | MATERIALS AND METHODS FOR DELIVERING COMPOSITIONS TO SELECTED TISSUES | The Regents of the University of California (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090208556-A1 | Porous photonic crystals for drug delivery to the eye | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE (US) | 2009-08-20 | — | — | US | disclosed |
| WO-2009009563-A9 | MATERIALS AND METHODS FOR DELIVERING COMPOSITIONS TO SELECTED TISSUES | UNIV CALIFORNIA (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009009563-A2 | MATERIALS AND METHODS FOR DELIVERING COMPOSITIONS TO SELECTED TISSUES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-01-15 | — | — | WO | disclosed |
| EP-1817003-A2 | POROUS PHOTONIC CRYSTALS FOR DRUG DELIVERY TO THE EYE | The Regents of the University of California (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006050221-A2 | POROUS PHOTONIC CRYSTALS FOR DRUG DELIVERY TO THE EYE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-05-11 | — | — | WO | disclosed |
| US-4228274-A | 1-Substituted glycopyranosides | MERCK & CO., INC. (US) | 1980-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000744-A1 | DRUG DELIVERY FORMULATIONS | PGR, FKBP1A, LPXN | MEN1 301/4885KMT2A 1886/4885ALDH1A1 3244/4885 |
| US-20210054017-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | GNE, FUT6, GALNT13 | MEN1 3580/4885KMT2A 1558/4885ALDH1A1 669/4885 |
| US-12171877-B2 | Materials and methods for delivering compositions to selected tissues | TNNC1, ALPP, PGF | MEN1 1808/4885KMT2A 4614/4885ALDH1A1 2303/4885 |
| US-20100196435-A1 | MATERIALS AND METHODS FOR DELIVERING COMPOSITIONS TO SELECTED TISSUES | TNNC1, ALPP, PGF | MEN1 1808/4885KMT2A 4614/4885ALDH1A1 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.